Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2027

Conditions

Biliary Tract Neoplasms

Interventions

DRUG

Envafolimab plus Gemcitabine&Cisplatin

Envafolimab a programmed death ligand immune check inhibitor Per Investigator decision

DRUG

Gemcitabine&Cisplatin

The standard of care for the patients with unresectable/metastatic biliary tract cancer

All Listed Sponsors

lead

3D Medicines (Sichuan) Co., Ltd.

INDUSTRY